115951-16-1

Basic information

• Product Name: 1-TERT-BUTOXYCARBONYLAMINO-CYCLOHEXANECARBOXYLIC ACID
• Synonyms: RARECHEM EM WB 0029;N-BOC-AMINOCYCLOHEXYLCARBOXYLIC ACID;N-ALPHA-T-BUTOXYCARBONYL-1-AMINO-CYCLOHEXANECARBOXYLIC ACID;N-ALPHA-T-BOC-1-AMINOCYCLOHEXANE CARBOXYLIC ACID;1-TERT-BUTOXYCARBONYLAMINO-CYCLOHEXANECARBOXYLIC ACID;1-BOC-AMINO-CYCLOHEXANE-1-CARBOXYLIC ACID;1-(BOC-AMINO)CYCLOHEXANECARBOXYLIC ACID;BOC-1-AMINOCYCLOHEXANE-1-CARBOXYLIC ACID
• CAS NO: 115951-16-1
• Molecular Formula: C₁₂H₂₁NO₄
• Molecular Weight: 243.3
• Product Categories: Amino Acids and Derivatives;Amino Acid Derivatives
• Mol File: 115951-16-1.mol
• Article Data: 24

Chemical Properties

• Melting Point: 176-178 °C (dec.)
• Boiling Point: 391.152 °C at 760 mmHg
• Flash Point: 190.362 °C
• Appearance: /
• Density: 1.134 g/cm³
• Vapor Pressure: 3.3E-07mmHg at 25°C
• Refractive Index: 1.496
• Storage Temp.: Store at 0°C
• BRN: 4189683
• CAS DataBase Reference: 1-TERT-BUTOXYCARBONYLAMINO-CYCLOHEXANECARBOXYLIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 1-TERT-BUTOXYCARBONYLAMINO-CYCLOHEXANECARBOXYLIC ACID(115951-16-1)
• EPA Substance Registry System: 1-TERT-BUTOXYCARBONYLAMINO-CYCLOHEXANECARBOXYLIC ACID(115951-16-1)

Safety Data

• WGK Germany: 3
• HazardClass: IRRITANT
• Hazardous Substances Data: 115951-16-1(Hazardous Substances Data)

Usage

Chemical Properties

White powder

InChI:InChI=1/C12H21NO4/c1-11(2,3)17-10(16)13-12(9(14)15)7-5-4-6-8-12/h4-8H2,1-3H3,(H,13,16)(H,14,15)

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 2756-85-6 1-aminocyclohexane carboxylic acid 
• 39692-17-6 1-amino-1-cyclohexane carboxylic acid hydrochloride 
• 702-62-5 spiro(imidazolidine-4,1'-cyclohexane)-2,5-dione 
• 1552-92-7 ethyl cyclohexylideneacetate 
• 108-94-1 cyclohexanone 
• 932-89-8 2-cyclohexylidene ethanol 

Downstream Products

• 128719-69-7 1-N-tert-butoxycarbonylamino-1-cyclohexane carbonyl-D-tryptophyl-L-leucine methyl ester 
• 158396-79-3 Boc-Ach-Thr-OBzl 
• 1025917-86-5 (S)-2-[(1-tert-Butoxycarbonylamino-cyclohexanecarbonyl)-amino]-3-(4-hydroxy-phenyl)-propionic acid methyl ester 
• 174077-39-5 1-[(1-tert-Butoxycarbonylamino-cyclohexanecarbonyl)-amino]-cyclohexanecarboxylic acid methyl ester 
• 220193-51-1 {1-[2-carbamoyl-1-(3-naphthalen-1-yl-propylcarbamoyl)-ethylcarbamoyl]-cyclohexyl}-carbamic acid tert-butyl ester 
• 223648-39-3 1-(tert-butoxycarbonylamino)cyclohexan-1-carboxamide 
• 804547-95-3 1-[[(N-tert-butoxycarbonylamino)cyclohexyl]carbonyl]-L-proline benzyl ester 
• 225122-33-8 N-(tert-butyloxycarbonyl)homocycloleucyl-glycine-nitrile 
• 871828-07-8 4-bromo-N-[1-(cyanomethyl-carbamoyl)-cyclohexyl]-benzamide 
• 871828-15-8 N-[1-(cyanomethylcarbamoyl)cyclohexyl]-4-(4,4,5,5-tetramethyl[1,3,2]dioxaborolan-2-yl)benzamide 

Relevant articles and documents

Novel TRPV1 antagonism/FAAH inhibition double-target drug, and preparation method and application thereof

The invention discloses a novel TRPV1 antagonism/FAAH inhibition double-target drug, and a preparation method and application thereof. The TRPV1 antagonism/FAAH inhibition double-target drug or a pharmaceutically acceptable salt thereof has a structural g

Discovery of Selective Inhibitors of Endoplasmic Reticulum Aminopeptidase 1

ERAP1 is an endoplasmic reticulum-resident zinc aminopeptidase that plays an important role in the immune system by trimming peptides for loading onto major histocompatibility complex proteins. Here, we report discovery of the first inhibitors selective for ERAP1 over its paralogues ERAP2 and IRAP. Compound 1 (N-(N-(2-(1H-indol-3-yl)ethyl)carbamimidoyl)-2,5-difluorobenzenesulfonamide) and compound 2 (1-(1-(4-acetylpiperazine-1-carbonyl)cyclohexyl)-3-(p-tolyl)urea) are competitive inhibitors of ERAP1 aminopeptidase activity. Compound 3 (4-methoxy-3-(N-(2-(piperidin-1-yl)-5-(trifluoromethyl)phenyl)sulfamoyl)benzoic acid) allosterically activates ERAP1's hydrolysis of fluorogenic and chromogenic amino acid substrates but competitively inhibits its activity toward a nonamer peptide representative of physiological substrates. Compounds 2 and 3 inhibit antigen presentation in a cellular assay. Compound 3 displays higher potency for an ERAP1 variant associated with increased risk of autoimmune disease. These inhibitors provide mechanistic insights into the determinants of specificity for ERAP1, ERAP2, and IRAP and offer a new therapeutic approach of specifically inhibiting ERAP1 activity in vivo.

C-3 NOVEL TRITERPENONE WITH C-28 REVERSE AMIDE DERIVATIVES AS HIV INHIBITORS

Formula (I) The invention relates to C-3 novel triterpenone with C-28 reverse amide derivatives, related compounds, and pharmaceutical compositions useful for the therapeutic treatment of viral diseases and particularly HIV mediated diseases.